iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02802943 |
|
Recruitment Status :
Recruiting
First Posted : June 16, 2016
Last Update Posted : September 17, 2019
|
Sponsor:
University Hospital Tuebingen
Collaborators:
Robert Bosch Gesellschaft für Medizinische Forschung mbH
Klinikum Stuttgart
Marienhospital Stuttgart
Katharinenhospital Stuttgart
Information provided by (Responsible Party):
University Hospital Tuebingen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 30, 2020 |
| Estimated Study Completion Date : | December 31, 2020 |